Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)
- 4 April 1988
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 152 (1), 411-416
- https://doi.org/10.1016/s0006-291x(88)80729-0
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Characterization of the common genetic defect in humans deficient in debrisoquine metabolismNature, 1988
- Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidationBiochemical Pharmacology, 1987
- High-performance liquid chromatographic assays for bufuralol 1′-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liverAnalytical Biochemistry, 1987
- Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomesBiochemical Pharmacology, 1985
- Genetically Determined Variability in Acetylation and Oxidation Therapeutic ImplicationsDrugs, 1985
- Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism) — Increased michaelis constant (km) and loss of stereoselectivity of bufuralol 1′-hydroxylation in poor metabolizersBiochemical and Biophysical Research Communications, 1984
- Competitive inhibition of sparteine oxidation in human liver by β-adrenoceptor antagonists and other cardiovascular drugsLife Sciences, 1984
- Evidence for an enzymatic defect in the 4-hydroxylation of debrisoquine by human liver.British Journal of Clinical Pharmacology, 1981
- A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population.Journal of Medical Genetics, 1980
- POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MANThe Lancet, 1977